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Introduction
Tenofovir disoproxil fumarate (TDF) is a nucleotide
analogue reverse transcriptase inhibitor (NtRTI), which
blocks reverse transcriptase, an enzyme found in HIV.
Since its approval for use in HIV by the FDA in 2001,
it has contributed to effective treatment in numerous
patients. The most common side effects include
nausea, vomiting, diarrhea, asthenia, abdominal pain
and hepatotoxicity. A less common side effect is
nephrotoxicity leading to Fanconi’s syndrome. Here is
an interesting case of Fanconi’s Syndrome caused by
Tenofovir.

Case
A 50-year-old Caucasian female with a past medical
history of HIV and Hepatitis C presented to the
Emergency Department with hypokalemia and acute
renal failure. She had been diagnosed with HIV in 2003
and was being managed on co-formulated Truvada
(Emtracitabine/Tenofovir) and Efavirenz since 2008.
She was previously on Lamivudine/Zidovudine and
Efavirenz, which were discontinued due to side effects.
Over the past month, the patient was noted to have
hypokalemia and worsening serum creatinine (sCr),
which was being treated with potassium supplements
and avoidance of NSAIDs. On presentation she denied
any diuretic use, nausea, vomiting, diarrhea, weakness,
fatigue, paralysis, palpitations, syncope, lightheadedness or chest pain.
The patient’s HIV was under good control (last CD4
count of 1400 cells/mm3 and viral load undetectable
at <20 copies/ml), and her viral load for hepatitis C was
negligible (HCV RNA quantitative real time PCR <43 IU/
ml). She did not have any history of seizure disorder,
refractory migraine or use of drugs such as zonisamide
or carbonic anhydrase inhibitors. Pertinent medications
included Truvada 1 Tablet every 48 hours and Efavirenz
600 mg at bedtime. She had no drug allergies. Social

history was only positive for 1 pack per day of cigarette
use for many years.
On physical exam the patient was afebrile and her vital
signs were stable. She appeared to be in no apparent
distress. She was alert and oriented to time, place and
self. She did not have any scleral icterus or thrush in
her throat. She had moist mucous membranes. Her
pulmonary, cardiovascular, abdominal and neurological
exams were normal. She did not have any costrovertebral angle tenderness. She also had no pedal edema.
Her laboratory data were as follows: sodium 135 mmol/L
(normal 135-146mmol/L), potassium 1.9 mmol/L
(normal 3.5-5mmol/L), chloride 97 mmol/L (89-109
mmol/L), bicarbonate 22 mmol/L (24-32 mmol/L), BUN
20 mg/dL (normal 7-26 mg/dL), creatinine1.7 mg/dL
(0.7-1.4 mg/dL), anion gap 16 mmol/L (4-16 mmol/L),
magnesium 1.9 mEq/L (1.3-2.1 mEq/L), phosphate 2
mg/dL (2.4-4.5 mg/dL)(low). Urinalysis showed yellow
urine with a pH of 7.0, 1+ Glucose, 1+ protein, urine
potassium 13 mmol/L, urine osmolality 211 mmol/L,
serum osmolality 293 mmol/L. Serum creatinine and
potassium in 2008 were 0.8 mg/dL and 3.6 mmol/L
respectively, and 1mg/dL and 3.5 mmol/L six months
ago. Renal ultrasound showed mildly echogenic
kidneys suggesting renal parenchymal disease.

Differential Diagnosis
and Hospital Course
Given her glycosuria, proteinuria, hypophosphatemia
in addition to hypokalemia and acute renal failure, a
diagnosis of renal tubular acidosis type 2 and Fanconi’s
Syndrome was made. The etiology of this was thought
to be her Tenofovir use (part of the Truvada combo);
she had been receiving this for the past 5 years. Based
on our consulting nephrologists recommendations, her
Truvada was discontinued, her potassium was repleted
with both intravenous and oral supplements, and her

The Medicine Forum | 61 5

renal function improved with intravenous hydration. At
the time of discharge her Creatinine was 1.1 mg/dL and
her potassium was 2.8 mmol/L. She was discharged
with oral potassium supplementation and appropriate
follow up with her infectious disease doctor.

Discussion
Tenofovir is available in combination with Emtricitabine
in a product with the brand name Truvada. It is also
available in a single tablet regimen, Atripla, which
contains Tenofovir, Emtricitabine and Efavirenz.
Tenofovir is the only NtRTI approved for use in HIV.1 It is
also approved for the treatment of chronic hepatitis B
and as pre-exposure prophylaxis against HIV infection.1
Tenofovir has been deemed a suitable NtRTI secondary
to less adverse effects on blood lipids and less
mitochondiral toxicity. It was also found to have less
renal toxicity in early randomized clinical trials.2 Although
initially there were concerns given Tenofovir’s molecular/
structural similarity to other nucleotide analogs Adefovir
and Cidofovir, which cause proximal tubulopathy by
decreasing mitochondrial DNA replication (inhibits
mtDNA polymerase), it was found that mtDNA depletion
was negligible with Tenofovir.3 However in other studies,
Tenofovir has been shown to be nephrotoxic to proximal
tubular cells.4 The discrepancy is thought to be secondary
to the strict inclusion and exclusion criteria applied in the
clinical trials.4
Nephrotoxicity from Tenofovir can result in proximal
tubular dysfunction with normal renal function, or with
acute or chronic renal failure. The renal failure can
happen months to years after starting the drug. The
major renal biopsy finding is proximal tubular injury,
ranging from mild and localized to diffuse and severe.
This is associated with varying degrees of chronic
tubulointerstitial scarring (i.e., tubular atrophy and
interstitial fibrosis).5
The proximal tubulopathy results in Fanconi’s syndrome,
either partial or complete. 6 Complete Fanconi’s
syndrome consists of renal tubular acidosis, glycosuria
with hypophosphatemia, aminoaciduria, hypouricemia
and tubular proteinuria. Renal function decline may
follow tubular dysfunction. 7 B2-microglobinuira is
prevalent. 8 Patients may have osteomalacia secondary
to phosphate wasting and calcitriol deficiency, since
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calcitriol is absorbed in the mitochondria of proximal
tubules.7,9 Our patient in the above-mentioned case had
most of these findings.
The incidence and prevalence of Tenofovir toxicity
is varied. A study conducted in 2006 by a Spanish
medical group found that 22% of tenofovir-treated
patients had tubular dysfunction as opposed to 12% of
naive HIV patients and 6% of HAART-treated patients.
A retrospective study of HIV-infected patients on
Tenofovir identified 1% whose sCr increased.10
Thus, in order to manage patients with HIV on
Tenofovir, one must be able to figure out who is at risk
of nephrotoxicity. Postmarketing clinical data analysis
showed that advanced age, low body weight, higher
serum creatinine levels before starting Tenofovir
treatment, comorbidities (diabetes, hypertension, HCV
coinfection), concomitant nephrotoxic medications,
advanced HIV infection (low CD4 counts, AIDS), and
male sex were risk factors for Tenofovir-induced GFR
reduction.2,10,11

Future Directions
Tenofovir alafenamide (TAF) is a pro-drug of Tenofovir
and is currently in Phase III clinical trials.12 Compared to
Tenofovir, TAF has increased HIV-1 activity, increased
intracellular Tenofovir diphosphate levels by 7 fold,
decreased circulating plasma Tenofovir levels by 90%,
which results in lower levels of Tenofovir in kidney
and bone tissue. This decrease will hopefully cause
less renal toxicity as well as decreased bone mineral
toxicity. In a recent phase 2 randomized, placebocontrolled trial, treatment naive HIV-1 infected
individuals were randomized 2:1 to receive Elvitegravir/
Cobicistat/Emtricitabine/TAF or Elvitegravir/Cobicistat/
Emtricitabine/Tenofovir. In the 24 week analysis, those
receiving the compound with TAF had high levels of
virologic suppression as well as a significantly smaller
increase in serum creatinine and smaller decreases in
bone mineral density of the hip and spine.

Key Points
Tenofovir is a widely used antiretroviral therapy, which,
unfortunately, can cause RTA type 2 and renal failure.
Although our patient had to stop an effective antiretroviral medication secondary to its side-effect of RTA
type 2 Fanconi’s syndrome, she may still be able to use
it in the near future if TAF gets approved.
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